
THE PRICING GAME: A COVID UPDATE!

Revisiting the Pricing Game

Price versus Value

The Lead in

Price vs Value



Drivers of intrinsic value

- Cashflows from existing assets
- Growth in cash flows
- Quality of Growth


Drivers of "the gap"

- Information
- Liquidity
- Corporate governance

Drivers of price

- Market moods & momentum
- Surface stories about fundamentals

Test 1: Are you pricing or valuing?



Test 2: Are you pricing or valuing?

Rating Buy

Europe Switzerland

Biotechnology Biotechnology

BB BIOTECH

Reuters Bloomberg BION.S BION SW Exchange Ticker SWX BION

Forecast Change

13 August 2013

Price at 12 Aug 2013 (CHF)	124.00
Price Target (CHF)	164.50
52-week range (CHF)	128.40 - 84.90

Strong sector and stock-picking continue

Impressive performance

Over the past two years, BB Biotech shares have roughly tripled, which could tempt investors to take profits. However, this performance has been well backed by a deserved revival of the biotech industry, encouraging fundamental news, M&A, and increased money flow into health care stocks. In addition, BBB returned to index outperformance by modifying its stock-picking approach. Hence, despite excellent performance, the shares still trade at a 23% discount to the net asset value of the portfolio. Hence, the shares are an attractive value vehicle to capture growth opportunities in an attractive sector.

Biotech industry remains attractive

With the re-rating of the pharma sector, investors have also showed increased interest in biotech stocks. Established biotech stocks have delivered encouraging financial results and approvals, while there has also been substantial industry consolidation, which is not surprising in times of "cheap" money and high liquidity. BB Biotech remains an attractive vehicle to capture the future potential of the biotech sector. In addition, investors benefit from a 23% discount to NAV and attractive cash distribution policy of 5% yield p.a. Hence, we reiterate our Buy on BB Biotech shares.

BB Biotech shares remain attractive

In the first 6M of 2013, BB Biotech increased its NAV by 36%, which marks good outperformance against the Nasdaq Biotech Index (NBI)'s 27%. This is a remarkable performance after 2012, when BBR's NAV increase of 45% also

Key changes

Target Price 106.50 to 164.50 † 54.5%

Source: Deutsche Bank

Price/price relative



Performance (%)	1m	3m	12m
Absolute	-1.4	5.4	37.4
SPI Swiss Performance IX	0.5	-1.4	26.4
Source: Deutsche Bank			

The determinants of value

What are the cashflows from existing assets?

- Equity: Cashflows after debt payments
- Firm: Cashflows before debt payments

What is the **value added** by growth assets? Equity: Growth in equity earnings/ cashflows Firm: Growth in operating earnings/ cashflows

How **risky are the cash flows** from both existing assets and growth assets? Equity: Risk in equity in the company Firm: Risk in the firm's operations

When will the firm become a **mature fiirm**, and what are the potential roadblocks?

The determinants of price

Mood and Momentum

Price is determined in large part by mood and momentum, which, in turn, are driven by behavioral factors (panic, fear, greed).

Liquidity & Trading Ease

While the value of an asset may not change much from period to period, liquidity and ease of trading can, and as it does, so will the price.

The Market Price

Incremental information

Since you make money on price changes, not price levels, the focus is on incremental information (news stories, rumors, gossip) and how it measures up, relative to expectations

Group Think

To the extent that pricing is about gauging what other investors will do, the price can be determined by the "herd".

1. Upper and Lower Bounds

- Since price is determined by demand and supply, and there is nothing that requires that those buying and selling in markets have to be constrained, at least in the near term, by fundamentals, it follows that there is no upper or lower bound to prices.
- Value on the other hand has both upper and lower bounds, with both bounds being set by expected cash flows, growth and risk. The upper bound is set by those who are more optimistic about a stock and the lower bound by those who are most pessimistic about that same stock, in terms of future expectations or liquidation value.
 - It is possible, for some stocks, especially early in the life cycle and with substantial uncertainty about the future, for the lower bound on value to be zero,
 - Stocks collectively cannot have that lower bound. For equities collectively to be worth nothing, you would require an apocalyptic scenario, one in which there is little point thinking about investments anyway.


2. Price is reactive, value is proactive

- Incremental Information versus Fundamental Information: Pricing forces can take information that, at least at first sight, seems insignificant to long term value and cause price changes that are disproportional. Thus, when the mood is upbeat, small pieces of good news can result in big jumps in stock prices, but if that mood turns sour, small pieces of bad news can cause large drops in stock prices.
- Reactive versus Proactive: Traders react to the incremental information to adjust the price and put little thought into whether the starting price itself has a basis to it. Value is driven by expectations of cash flows, growth and risk, and information has to be used to reassess those expectations, a more difficult task, but one that forces you to separate the wheat from the chaff.

3. Price may never converge on value...

- Old time value investors live by the adage that the price can go up and down, with little relationship to value, but that it will eventually converge to value.
- Absent a catalyst causing the convergence, price will not only diverge from value in the short term, but it could do so in the long term. Keynes was close to the truth when he said that the "market can stay irrational longer than you and I can stay solvent".
- So what is it that keeps investors toiling at the fundamentals, hoping to get rewarded? The answer is faith, faith that they can estimate value and faith that the price will adjust to value. It is faith because I can offer you no proof for either proposition, and it is faith, because its strength will be tested by markets like this one.

Deconstructing Pricing



To be a better pricer, here are four suggestions

- Check your multiple or consistency/uniformity
 - In use, the same multiple can be defined in different ways by different users. When comparing and using multiples, estimated by someone else, it is critical that we understand how the multiples have been estimated
- Look at all the data, not just the key statistics
 - Too many people who use a multiple have no idea what its cross sectional distribution is. If you do not know what the cross sectional distribution of a multiple is, it is difficult to look at a number and pass judgment on whether it is too high or low.
- Don't forget the fundamentals ultimately matter
 - It is critical that we understand the fundamentals that drive each multiple, and the nature of the relationship between the multiple and each variable.
- Don't define comparables based only on sector
 - Defining the comparable universe and controlling for differences is far more difficult in practice than it is in theory.

1. Check the Multiple

- Is the multiple consistently defined?
 - The consistency principle: Both the value (the numerator) and the standardizing variable (the denominator) should be to the same claimholders in the firm. In other words, the value of equity should be divided by equity earnings or equity book value, and firm value should be divided by firm earnings or book value.
 - The cost of mismatching: Assets that are not cheap(expensive) will look cheap (expensive), because your mismatch will skew the numbers.
- Is the multiple uniformly estimated?
 - The uniformity rule: The variables used in defining the multiple should be estimated uniformly across assets in the "comparable firm" list.
 - The cost of ignoring this rule: You will be comparing non-comparable numbers and drawing all the wrong conclusions.


Consistency Rules

- Equity/Firm: The first is that if the numerator is an equity value, the denominator should be an equity value as well, while if the numerator is a firm or enterprise value, the denominator has to be an operating value. Thus, PE (market cap, an equity value, is divided by earnings per share, an equity value) and EV to EBITDA (EV is a market value of operating assets and EBITDA is a measure of operating cash flow) are consistent, but Price to EBITDA is an inconsistent abomination and Price to Sales is almost as badly constructed.
- <u>Timing</u>: The second is that multiples are constructed for comparisons across companies, not as stand alone measures. It follows therefore that you should be consistent in how you measure your scaling variable (revenues, book value, earnings) across companies. Thus, if you choose to use trailing earnings for your company to compute PE, you have to use trailing earnings for all your companies.

2. Play Moneyball: Let the numbers talk (not the analysts)

- What is the average and standard deviation for this multiple, across the universe (market)?
- What is the median for this multiple?
 - The median for this multiple is often a more reliable comparison point.
- How large are the outliers to the distribution, and how do we deal with the outliers?
 - Throwing out the outliers may seem like an obvious solution, but if the outliers all lie on one side of the distribution (they usually are large positive numbers), this can lead to a biased estimate.
- Are there cases where the multiple cannot be estimated? Will ignoring these cases lead to a biased estimate of the multiple?
- How has this multiple changed over time?


PE Ratios at the start of 2020



3. Understand your "implicit" assumptions

- What are the fundamentals that determine and drive these multiples?
 - Proposition 1: Embedded in every multiple are all of the variables that drive every discounted cash flow valuation - growth, risk and cash flow patterns.
 - In fact, using a simple discounted cash flow model and basic algebra should yield the fundamentals that drive a multiple
- How do changes in these fundamentals change the multiple?
 - The relationship between a fundamental (like growth) and a multiple (such as PE) is seldom linear. For example, if firm A has twice the growth rate of firm B, it will generally not trade at twice its PE ratio
 - Proposition 2: It is impossible to properly compare firms on a multiple, if we do not know the nature of the relationship between fundamentals and the multiple.

The Determinants of Multiples...




4. Define "comparable" broadly & control for differences

- Given the firm that we are valuing, what is a "comparable" firm?
 - While traditional analysis is built on the premise that firms in the same sector are comparable firms, valuation theory would suggest that a comparable firm is one which is similar to the one being analyzed in terms of fundamentals.
 - Proposition 4: There is no reason why a firm cannot be compared with another firm in a very different business, if the two firms have the same risk, growth and cash flow characteristics.
- Given the comparable firms, how do we adjust for differences across firms on the fundamentals?
 - Proposition 5: It is impossible to find an exactly identical firm to the one you are valuing.

A COVID Break

Crisis times?

The lead up to the crisis... On February 14...



A Crisis hits.. Damage assessment on March 20, 2020

				% CI	hange		
	Index	Country/Region	Level on 3/20	3/13-3/20	Last Month		
	S&P 500	US	2305	-14.98%	-30.94%		
	NASDAQ	US	6994	-12.52%	-25.96%		
Americas	TSX	Canada	11852	-13.59%	-33.58%		
	IPC Mexico	Mexico	34270	-10.02%	-23.51%		
	Bovespa	Brazil	67069	-18.88%	-41.00%		
	FTSE 100	UK	5191	-3.27%	-29.89%		
Furana	DAX	Germany	8929	-3.28%	-34.25%		
Europe	CAC 40	France	4131	-1.67%	-33.31%		
	S&P Euro 350	Europe	1181	1.59%	-31.32%		
	Nikkei 225	Japan	16553	-10.81%	-29.50%		
Asia	Shanghai 50	China	2628	-6.09%	-11.45%		
ASIU	Hang Seng	Hong Kong	22805	-5.11%	-16.49%		
	BSE	India	29916	-12.28%	-25.88%		
Australia	ASX 50	Australia	4828	-12.87%	-31.97%		
& NZ	NZX 50	New Zealand	9202	-6.36%	-23.79%		
Africa	FTSE JSE top 40	South Africa	36302	-8.04%	-29.62%		
Africa	NSE All-Share	Nigeria	22198	-2.36%	-18.95%		


A Come back or False Security? From 3/17-4/17

				% CF	nange
	Index	Country/Region	Level on 4/17	4-10-4/17	3/17-4/17
	S&P 500	US	2875	2.68%	4.09%
	NASDAQ 100	US	8832	0.85%	6.00%
Americas	TSX	Canada	14360	2.02%	22.51%
	IPC Mexico	Mexico	34743	0.37%	-2.22%
	iBovespa	Brazil	78990	0.20%	18.08%
	FTSE 100	UK	5787	-0.08%	13.90%
Europo	DAX	Germany	10626	-0.66%	25.87%
Europe	CAC 40	France	4499	-0.66%	20.27%
	S&P Europe 350	Europe	1341	-0.11%	19.55%
	Nikkei 225	Japan	19897	2.05%	18.96%
Asia	Shanghai 50	China	2809	2.15%	6.98%
Asia	Hang Seng	Hong Kong	24380	-0.23%	9.37%
	Sensex	India	27591	2.93%	9.42%
Australia	ASX 200	Australia	5068	-0.01%	10.79%
& NZ	NZX 50	New Zealand	9935	7.21%	14.00%
Africa	FTSE/JSE TOP 40	South Africa	44599	-1.18%	29.75%
Africa	NSE All Share	Nigeria	21099	1.75%	1.60%


A Flight to Safety? Treasuries

	Yields on US Treasuries													
Maturity	2/14/20	4/3/20	4/10/20	4/17/20										
3 month	1.58%	0.10%	0.25%	0.12%										
2 year	1.42%	0.23%	0.23%	0.20%										
5 year	1.42%	0.39%	0.41%	0.36%										
10 year	1.59%	0.62%	0.73%	0.65%										
20 year	1.89%	1.05%	1.15%	1.08%										
30 year	2.04%	1.24%	1.35%	1.27%										
		Yield curv	e slope											
2 yr - 3 month	-0.16%	0.13%	-0.02%	0.08%										
10 yr - 2 yr	0.17%	0.39%	0.50%	0.45%										
30 yr - 10 yr	0.45%	0.62%	0.62%	0.62%										

Divergent Stories: Oil and Copper




Crisis Asset: Gold and Bitcoin




The price of risk: Determinants

- The price of risk changes on a day-to-day basis, and is determined by a combination of variables that encompass almost everything going on in the world from
 - uncertainty about future economic growth (more uncertainty -> higher price for risk) to
 - political stability (more instability -> higher price for risk) to
 - worries about catastrophes/disasters (more worries -> higher price for risk) to
 - investor risk aversion (greater risk aversion -> higher price for risk) to
 - information availability/reliability (less reliable and accessible information -> higher risk premiums).
- The more general point though that emerges from identifying the determinants is that changes in these determinants will play out as changing prices for risk, and since investing and valuation has to be based upon current and update prices for risk, you need measurement approaches that capture these day-to-day changes.


Bond Default Spreads during the 2008 crisis




Bond Market Default Spreads: The COVID crisis




An Equity Market Price of Risk



The 2008 Crisis



The Price of Risk: Equities



Equities: By Region

								ŝ	Mkt Cap: 4	1/3-4/17	į	Mkt Cap: 2/2	14 - 4/17
Sub Region	Number of firms	М	kt Cap (2/14)	М	kt Cap (4/3)	М	ct Cap (4/17)	\$	Change	% Change		\$ Change	% Change
Africa	652	\$	579,706	\$	352,644	\$	381,099	\$	28,455	8.07%	\$	(198,607)	-34.26%
Australia & NZ	1,356	\$	1,617,545	\$	1,038,217	\$	1,193,976	\$	155,759	15.00%	\$	(423,569)	-26.19%
Canada	1,576	\$	2,234,720	\$	1,508,434	\$	1,690,178	\$	181,744	12.05%	\$	(544,542)	-24.37%
China	6,161	\$	14,027,134	\$	12,659,745	\$	13,253,719	\$	593,974	4.69%	\$	(773,415)	-5.51%
Eastern Europe & Russia	414	\$	816,760	\$	564,470	\$	580,852	\$	16,382	2.90%	\$	(235,908)	-28.88%
EU & Environs	4,770	\$	13,667,991	\$	9,893,062	\$	10,757,788	\$	864,727	8.74%	\$	(2,910,202)	-21.29%
India	1,941	\$	2,201,867	\$	1,410,184	\$	1,602,062	\$	191,879	13.61%	\$	(599,805)	-27.24%
Japan	3,811	\$	6,041,538	\$	4,742,114	\$	5,232,948	\$	490,834	10.35%	\$	(808,590)	-13.38%
Latin America & Caribbean	934	\$	2,373,918	\$	1,376,023	\$	1,527,171	\$	151,148	10.98%	\$	(846,747)	-35.67%
Middle East	1,150	\$	3,073,924	\$	2,719,466	\$	2,665,047	\$	(54,419)	-2.00%	\$	(408,877)	-13.30%
Small Asia	7,694	\$	5,061,281	\$	3,772,641	\$	4,175,157	\$	402,516	10.67%	\$	(886,124)	-17.51%
UK	1,094	\$	3,072,497	\$	2,052,755	\$	2,298,374	\$	245,618	11.97%	\$	(774,123)	-25.20%
United States	4,928	\$	35,642,353	\$	25,634,234	\$	29,784,527	\$4	4,150,293	16.19%	\$	(5,857,826)	-16.44%
Global	36,481	\$	90,411,233	\$	67,723,989	\$	75,142,899	\$7	7,418,910	10.95%	\$(15,268,334)	-16.89%

Equities: By Sector

					Mkt Cap: 4/3-4	/17 1	Mkt Cap: 2/2	14 - 4/17
Primary Sector	Number of firms	Number of firms Mkt Cap (2/14) I		Mkt Cap (4/17)	\$ Change % Cl	hange \$	Change	% Change
Communication Services	1,682	\$ 7,341,638	\$ 5,771,726	\$ 6,396,994	\$ 625,268 10	.83% \$	(944,644)	-12.87%
Consumer Discretionary	4,945	\$ 10,158,898	\$ 7,308,734	\$ 8,555,018	\$1,246,284 17	.05% \$	(1,603,880)	-15.79%
Consumer Staples	2,298	\$ 7,118,491	\$ 6,080,159	\$ 6,548,231	\$ 468,073 7.	70% \$	(570,260)	-8.01%
Energy	1,316	\$ 5,938,328	\$ 4,339,633	\$ 4,383,093	\$ 43,460 1.	00% \$	(1,555,234)	-26.19%
Financials	3,844	\$ 14,919,508	\$ 10,094,701	\$ 10,933,915	\$ 839,214 8.	31% \$	(3,985,593)	-26.71%
Global	36,481	\$ 90,411,233	\$ 67,723,989	\$ 75,142,899	\$7,418,910 10	.95% \$(2	15,268,334)	-16.89%
Health Care	3,411	\$ 8,968,840	\$ 7,582,188	\$ 8,581,301	\$ 999,113 13	.18% \$	(387,539)	-4.32%
Industrials	6,564	\$ 10,121,550	\$ 7,170,567	\$ 7,951,424	\$ 780,857 10	.89% \$	(2,170,126)	-21.44%
Information Technology	4,875	\$ 13,601,118	\$ 10,328,554	\$ 11,798,990	\$1,470,437 14	.24% \$	(1,802,128)	-13.25%
Materials	4,414	\$ 4,991,381	\$ 3,736,573	\$ 4,139,741	\$ 403,168 10	.79% \$	(851,640)	-17.06%
Real Estate	2,311	\$ 4,050,062	\$ 2,859,551	\$ 3,164,030	\$ 304,479 10	.65% \$	(886,032)	-21.88%
Utilities	817	\$ 3,200,581	\$ 2,450,935	\$ 2,689,435	\$ 238,500 9.	73% \$	(511,146)	-15.97%
All firms	36,481	\$ 90,411,233	\$ 67,723,989	\$ 75,142,899	\$7,418,910 10	.95% \$(2	15,268,334)	-16.89%

Equities: Most & least damaged Industries


				ontes.c				2000 No. 2000 Eng 1970 No.					
				Wors	t Pe	erforming Inc	lustries (2/1	L4 - 4/17)					
							Mkt Cap:	4/3-4/17	Mkt Cap: 2/14 - 4/17				
Industry	Mkt	Cap (2/14)	Mk	t Cap (4/3)	Mk	t Cap (4/17)	\$ Change	% Change	\$ Change	% Change			
Oil/Gas (Production and Exploration)	\$	692,554	\$	386,341	\$	404,834	\$ 18,493	4.79%	\$ (287,719)	-41.54%			
Homebuilding	\$	247,004	\$	126,947	\$	154,145	\$ 27,198	21.43%	\$ (92,859)	-37.59%			
Air Transport	\$	559,439	\$	306,560	\$	350,468	\$ 43,908	14.32%	\$ (208,971)	-37.35%			
Broadcasting	\$	164,761	\$	93,291	\$	107,844	\$ 14,553	15.60%	\$ (56,917)	-34.55%			
Oilfield Svcs/Equip.	\$	741,428	\$	445,056	\$	488,541	\$ 43,485	9.77%	\$ (252,887)	-34.11%			
Food Wholesalers	\$	93,056	\$	52,910	\$	61,559	\$ 8,649	16.35%	\$ (31,497)	-33.85%			
Oil/Gas Distribution	\$	653,462	\$	386,630	\$	437,227	\$ 50,597	13.09%	\$ (216,235)	-33.09%			
Hotel/Gaming	\$	717,777	\$	394,003	\$	490,025	\$ 96,022	24.37%	\$ (227,752)	-31.73%			
Aerospace/Defense	\$	1,217,331	\$	683,209	\$	832,292	\$149,082	21.82%	\$ (385,039)	-31.63%			
Reinsurance	\$	180,550	\$	109,101	\$	123,655	\$ 14,554	13.34%	\$ (56,895)	-31.51%			
	Best Performing Industries (2/14 - 4/17)												
							Mkt Cap:	4/3-4/17	Mkt Cap: 2	/14 - 4/17			
Industry	Mkt	Cap (2/14)	Mk	t Cap (4/3)	Mk	t Cap (4/17)	\$ Change	% Change	\$ Change	% Change			
Retail (Online)	\$	2,455,790	\$	2,081,460	\$	2,483,956	\$402,496	19.34%	\$ 28,166	1.15%			
Drugs (Biotechnology)	\$	1,409,166	\$	1,242,047	\$	1,422,584	\$ 180,537	14.54%	\$ 13,417	0.95%			
Precious Metals	\$	418,906	\$	350,674	\$	417,290	\$ 66,616	19.00%	\$ (1,616)	-0.39%			
Software (Internet)	\$	226,911	\$	173,926	\$	224,558	\$ 50,632	29.11%	\$ (2,353)	-1.04%			
Heathcare Information and Technolog	\$	772,828	\$	656,136	\$	759,471	\$103,335	15.75%	\$ (13,357)	-1.73%			
Drugs (Pharmaceutical)	\$	3,623,939	\$	3,190,552	\$	3,497,146	\$306,594	9.61%	\$ (126,793)	-3.50%			
Food Processing	\$	1,792,176	\$	1,617,124	\$	1,718,626	\$101,502	6.28%	\$ (73,550)	-4.10%			
Retail (General)	\$	1,054,814	\$	903,932	\$	1,004,714	\$100,781	11.15%	\$ (50,100)	-4.75%			
Healthcare Products	\$	1,829,639	\$	1,500,672	\$	1,723,383	\$222,710	14.84%	\$ (106,257)	-5.81%			
Household Products	\$	1,453,345	\$	1,260,149	\$	1,358,804	\$ 98,655	7.83%	\$ (94,541)	-6.51%			

Equities: Net Debt Ratios

								Mkt Cap: 4	1/3-4/17	Mkt Cap: 2/	14 - 4/17
Net Debt to EBITDA	Number of firms	Mk	t Cap (2/14)	Mk	kt Cap (4/3)	M	ct Cap (4/17)	\$ Change	% Change	\$ Change	% Change
Bottom decile	2,549	\$	2,438,332	\$	2,001,936	\$	2,180,230	\$ 178,294	8.91%	\$ (258,102)	-10.59%
2nd decile	2,550	\$	5,077,547	\$	4,147,232	\$	4,602,779	\$ 455,548	10.98%	\$ (474,768)	-9.35%
3rd decile	2,550	\$	8,075,126	\$	6,468,172	\$	7,272,203	\$ 804,031	12.43%	\$ (802,922)	-9.94%
4th decile	2,549	\$	8,668,340	\$	7,068,705	\$	7,520,089	\$ 451,383	6.39%	\$ (1,148,252)	-13.25%
5th decile	2,550	\$	13,089,926	\$	10,206,289	\$	11,465,333	\$ 1,259,044	12.34%	\$ (1,624,593)	-12.41%
6th decile	2,550	\$	12,069,805	\$	9,099,941	\$	10,091,424	\$ 991,483	10.90%	\$ (1,978,382)	-16.39%
7th decile	2,549	\$	10,285,530	\$	7,492,767	\$	8,351,601	\$ 858,833	11.46%	\$ (1,933,929)	-18.80%
8th decile	2,550	\$	8,192,083	\$	5,881,602	\$	6,639,747	\$ 758,145	12.89%	\$ (1,552,336)	-18.95%
9th decile	2,550	\$	6,872,631	\$	4,676,233	\$	5,291,833	\$ 615,600	13.16%	\$ (1,580,798)	-23.00%
Top decile	2,550	\$	2,620,044	\$	1,721,135	\$	1,907,582	\$ 186,447	10.83%	\$ (712,462)	-27.19%
EBITDA negative	10,984	\$	13,021,868	\$	8,959,977	\$	9,820,078	\$ 860,101	9.60%	\$ (3,201,790)	-24.59%

Pricing in a Crisis Market


Game plan?




A Pricing Market?

- I have argued that just because uncertainty has increased, there is no excuse for abandoning valuation first principles or process and argued that you can still value companies, albeit with a much wider range of outcomes.
- One common counter that I got to this argument was that valuation was pointless, when the uncertainty was so great and while most did not bother presenting alternatives, my guess is that many will fall back on pricing metrics to decide whether and what to buy or sell.
- Put simply, they will use a PE ratio or an enterprise value multiple of EBITDA or sales to decide what stocks to buy or sell, acting under the delusion that this will allow them to escape having to make assumptions in the future.


Pricing a Market: The S&P 500 at the start of 2020



Bringing in the alternatives...



The Tie Breaker: E/P Ratios , T.Bond Rates and Term Structure: Updated..



Regression Results

	EP	T.Bond	T.Bill
EP	1.0000		5
T.Bond	0.6214	1.0000	9 = = =
Bond - Bill	-0.1283	-0.0739	1.0000

Correlation between E/P and interest rates

In the following regression, using 1960-2019 data, we regress E/P ratios against the level of T.Bond rates and a term structure variable (T.Bond - T.Bill rate)

R squared = 39.29%

☐ Going back to 2008, this is what the regression looked like:

$$E/P = 2.56\% + 0.7044$$
 T.Bond Rate $- 0.3289$ (T.Bond Rate-T.Bill Rate) (4.71) (7.10) (1.46)

R squared = 50.71%

The R-squared has dropped and the differential with the T.Bill rate has lost significance. How would you read this result?

The Timing Effect: Pricing in a Crisis

Market Crises and Pricing Phase 3: The New Normal Phase 1: The Shock Phase 2: The Adjustment Market stays volatilie, as Market volatility subsides as Market price drops, as crisis Market investors get more comfortable leads investors to reprice risk investors use information to Reaction with their expectations. and reassess future cash flows. revisit & adjust expectations Earnings reports contain first Operating numbers reflect pre-Companies report actual Scaling indications of crisis effects & crisis state & analysts/firms are numbers for the crisis period Variable analysts/firms offer forecasts too uncertain to offer guidance of future operating results. Stocks will look cheaper on a Investors start to focus on Trailing multiples will reflect trailing basis, as market prices forward multiples, which will updated operating results and Pricing drop. Without guidance, much higher from trailing will be much higher than pre-**Effects** forward multiples cannot be values. With losses, revenues crisis or normalized values, will displace earnings as the computed. making stocks look expensive. sccaling variable. Use forward multiples, or if you Shift to really forward Shift to multiples of forward Good (normalized) multiples or stay earnings (but be willing to don't trust the forward Practice with trailing multiples. estimates, to revenue multiples make the estimates yourself).

Regional Pricing: The COVID effect

	Market Co	pita	lization		Trailing Ne	et Income	2	Traili	ng PE		Enterp	rise	Value		Trailing I	Revenues	EV/S	Sales
Sub Region	1/1/20		4/17/20	LTM thru 1/1/20 LTM thru 4/17/20 1/		1/1/20	1/1/20 4/17/20		1/1/20		4/17/20	LTM thru 1/1/20		LTM thru 4/17/20	1/1/20	4/17/20		
Africa	\$ 602,927	\$	381,099	\$	35,530	\$	38,724	16.97	9.84	\$	598,016	\$	386,863	\$	385,783	\$ 429,492	1.55	0.90
Australia & NZ	\$ 1,587,941	\$	1,193,976	\$	76,536	\$	70,092	20.75	17.03	\$	2,052,175	\$	1,770,472	\$	683,728	\$ 732,201	3.00	2.42
Canada	\$ 2,167,437	\$	1,690,178	\$	94,098	\$	110,956	23.03	15.23	\$	1,930,814	\$	1,695,978	\$	1,242,344	\$ 1,353,786	1.55	1.25
China	\$ 13,922,636	\$	13,253,719	\$	772,575	\$	828,606	18.02	16.00	\$	15,945,308	\$	15,957,070	\$	9,302,106	\$ 9,967,255	1.71	1.60
Eastern Europe & Russia	\$ 826,177	\$	580,852	\$	111,656	\$	131,695	7.40	4.41	\$	916,769	\$	707,384	\$	819,619	\$ 913,013	1.12	0.77
EU & Environs	\$ 13,542,156	\$	10,757,788	\$	715,323	\$	744,298	18.93	14.45	\$	16,890,750	\$	14,809,760	\$ 1	0,766,716	\$ 11,241,700	1.57	1.32
India	\$ 2,168,366	\$	1,602,062	\$	51,119	\$	53,477	42.42	29.96	\$	2,947,357	\$	2,351,699	\$	821,927	\$ 1,292,910	3.59	1.82
Japan	\$ 6,156,869	\$	5,232,948	\$	414,961	\$	358,188	14.84	14.61	\$	6,256,725	\$	5,693,556	\$	7,446,882	\$ 7,673,662	0.84	0.74
Latin America & Caribbean	\$ 2,422,143	\$	1,527,171	\$	134,160	\$	134,678	18.05	11.34	\$	3,860,250	\$	2,671,959	\$	1,578,743	\$ 1,628,911	2.45	1.64
Middle East	\$ 3,211,880	\$	2,665,047	\$	189,723	\$	166,013	16.93	16.05	\$	3,176,350	\$	2,763,122	\$	939,171	\$ 939,350	3.38	2.94
Small Asia	\$ 5,195,524	\$	4,175,157	\$	328,180	\$	273,916	15.83	15.24	\$	5,360,207	\$	4,728,309	\$	4,990,894	\$ 5,069,035	1.07	0.93
UK	\$ 3,131,108	\$	2,298,374	\$	140,987	\$	136,642	22.21	16.82	\$	2,943,496	\$	2,464,666	\$	2,086,704	\$ 2,387,791	1.41	1.03
United States	\$ 34,066,742	\$	29,784,527	\$	1,326,457	\$	1,330,281	25.68	22.39	\$	43,454,615	\$	41,102,137	\$ 1	5,594,487	\$ 16,315,385	2.79	2.52
Global	\$ 89,001,908	\$	75,142,899	\$	4,391,305	\$	4,377,566	20.27	17.17	\$	106,332,834	\$	97,102,977	\$ 5	6,659,105	\$ 59,944,491	1.88	1.62

Sector Pricing: A COVID update

	Market Co	apito	alization		Trailing No	et Ind	come	Trailir	ig PE	Enterp	rise	Value	Trailing F	Revenues	EV/S	Sales
Primary Sector	1/1/20		4/17/20	LTI	M thru 1/1/20	LTN	Л thru 4/17/20	1/1/20	4/17/20	1/1/20		4/17/20	LTM thru 1/1/20	LTM thru 4/17/20	1/1/20	4/17/20
Communication Services	\$ 7,061,144	\$	6,396,994	\$	272,240	\$	268,340	25.94	23.84	\$ 8,394,815	\$	8,204,313	\$ 3,075,462	\$ 3,275,528	2.73	2.50
Consumer Discretionary	\$ 10,001,063	\$	8,555,018	\$	400,379	\$	422,756	24.98	20.24	\$ 11,670,561	\$	10,923,729	\$ 8,521,352	\$ 8,837,248	1.37	1.24
Consumer Staples	\$ 7,119,228	\$	6,548,231	\$	253,891	\$	252,124	28.04	25.97	\$ 8,249,126	\$	7,914,722	\$ 5,338,559	\$ 5,590,613	1.55	1.42
Energy	\$ 6,451,348	\$	4,383,093	\$	432,428	\$	324,381	14.92	13.51	\$ 7,947,389	\$	6,218,676	\$ 6,101,367	\$ 6,159,010	1.30	1.01
Financials	\$ 15,098,560	\$	10,933,915	\$	1,176,914	\$	1,389,056	12.83	7.87	\$ 17,472,728	\$	14,789,327	\$ 7,181,276	\$ 8,270,695	2.43	1.79
Global	\$ 89,001,908	\$	75,142,899	\$	4,391,305	\$	4,377,566	20.27	17.17	\$ 106,332,834	\$	97,102,977	\$ 56,659,105	\$ 59,944,491	1.88	1.62
Health Care	\$ 8,632,427	\$	8,581,301	\$	187,642	\$	218,959	46.00	39.19	\$ 9,283,692	\$	9,527,167	\$ 3,427,878	\$ 3,884,560	2.71	2.45
Industrials	\$ 10,017,689	\$	7,951,424	\$	492,859	\$	450,654	20.33	17.64	\$ 12,471,645	\$	11,013,498	\$ 9,882,375	\$ 10,347,296	1.26	1.06
Information Technology	\$ 12,471,842	\$	11,798,990	\$	436,974	\$	404,289	28.54	29.18	\$ 12,549,738	\$	12,140,677	\$ 4,716,370	\$ 4,860,140	2.66	2.50
Materials	\$ 5,122,449	\$	4,139,741	\$	328,775	\$	220,595	15.58	18.77	\$ 6,455,495	\$	5,541,436	\$ 4,727,861	\$ 4,787,420	1.37	1.16
Real Estate	\$ 3,953,469	\$	3,164,030	\$	271,496	\$	255,331	14.56	12.39	\$ 6,549,674	\$	5,752,049	\$ 1,445,509	\$ 1,618,764	4.53	3.55
Utilities	\$ 3,071,852	\$	2,689,435	\$	137,701	\$	171,080	22.31	15.72	\$ 5,287,148	\$	5,076,670	\$ 2,241,086	\$ 2,313,215	2.36	2.19
All firms	\$ 89,001,908	\$	75,142,899	\$	4,391,305	\$	4,377,566	20.27	17.17	\$ 106,332,834	\$	97,102,977	\$ 56,659,105	\$ 59,944,491	1.88	1.62

Pricing: A Wrap

- As companies start to report their first quarter earnings, you are starting to get a glimpse of the damage created by the crisis and my guess is that you will start to see more analysts and companies start to forecast forward numbers.
 - For those companies where forward earnings are positive, you can switch to forward PE ratios, but expect these numbers to be much, much higher than historical norms.
 - For those companies that have negative forward earnings, you will see revenue multiples or creative variations on future earnings.
- Later this year, as companies report numbers for the second and third quarters of 2020, the trailing operating numbers will finally catch up with the crisis, and you may be able to shift back to trailing multiples.
- Put simply, if you are abandoning or refusing to do intrinsic valuation, because you feel uncomfortable with having to make assumptions, the same uncertainty is going to pervade your pricing as well.